logo
Plus   Neg
Share
Email

Lilly : FDA Approves Emgality To Treat Episodic Cluster Headache In Adults

Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration approved Emgality or galcanezumab-gnlm injection (300 mg) for the treatment of episodic cluster headache in adults.

The company noted that Emgality will be available to patients for pickup at retail pharmacies. The U.S. list price of Emgality for the treatment of episodic cluster headache is the same per milligram as the migraine indication.

Emgality was first approved by the FDA in September 2018 for the preventive treatment of migraine in adults and is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google on Wednesday announced new restrictions on political advertisers around the world. The company has joined Twitter in revising its political ad rules ahead of the election season British luxury car giant Aston Martin unveiled its first SUV at an event in Los Angeles and at a simultaneous event in Beijing. The DBX SUV comes with an aluminium body with a typical Aston Martin grille flanked by LED headlights with LED DRLs. "I can't emphasize enough how incredibly exciting... Google has rolled out an audio news service for Google Assistant, called 'Your News Update,' which will read out a user's customized news feed. According to the tech giant, 'Your News Update' is a smarter way to listen to the news hosted by the Google Assistant. The customized news feed will deliver stories from a variety of media partners, including CBS, Politico, Fox News and CNN.
Follow RTT
>